Activator protein-2 in carcinogenesis with a special reference to breast cancer - A mini review

International Journal of Cancer

Volumn 120, Issue 10, 2007, Pages 2061-2067

  Pellikainen, Johanna M ^a,b   Kosma, Veli Matti ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Activator protein 2; Breast cancer; Carcinogenesis; HER2; Prognosis

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR AP 2ALPHA; TRANSCRIPTION FACTOR AP 2BETA; TRANSCRIPTION FACTOR AP 2GAMMA; UNCLASSIFIED DRUG;

APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; BREAST DEVELOPMENT; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE CONTROL; GERM CELL TUMOR; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY MECHANISM; SHORT SURVEY; TESTIS CANCER;

ANIMALS; BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENES, ERBB-2; HUMANS; MICE; RECEPTORS, ESTROGEN; TRANSCRIPTION FACTOR AP-2;

EID: 34147120555     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22648     Document Type: Short Survey

References (117)

1. Mitchell PJ, Wang C, Tjian R. Positive and negative regulation of transcription in vitro: enhancer-binding protein AP-2 is inhibited by SV40 T antigen. Cell 1987;50:847-61.
2. Williams T, Admon A, Luscher B, Tjian R. Cloning and expression of AP-2, a cell-type-specific transcription factor that activates inducible enhancer elements. Genes Dev 1988;2:1557-69.
3. Imagawa M, Chiu R, Karin M. Transcription factor AP-2 mediates induction by two different signal- transduction pathways: protein kinase C and cAMP. Cell 1987;51:251-60.
4. Luscher B, Mitchell PJ, Williams T, Tjian R. Regulation of transcription factor AP-2 by the morphogen retinoic acid and by second messengers. Genes Dev 1989;3:1507-17.
5. Cheng C, Ying K, Xu M, Zhao W, Zhou Z, Huang Y, Wang W, Xu J, Zeng L, Xie Y, Mao Y. Cloning and characterization of a novel human transcription factor AP-2 beta like gene (TFAP2BL1). Int J Biochem Cell Biol 2002;34:78-86.
6. Moser M, Imhof A, Pscherer A, Bauer R, Amselgruber W, Sinowatz F, Hofstadter F, Schule R, Buettner R. Cloning and characterization of a second AP-2 transcription factor: AP-2 beta. Development 1995;121:2779-88.
7. Oulad-Abdelghani M, Bouillet P, Chazaud C, Dolle P, Chambon P. AP-2: a novel AP-2-related transcription factor induced by retinoic acid during differentiation of P19 embryonal carcinoma cells. Exp Cell Res 1996;225:338-47.
8. Gaynor RB, Muchardt C, Xia YR, Klisak I, Mohandas T, Sparkes RS, Lusis AJ. Localization of the gene for the DNA-binding protein AP-2 to human chromosome 6p22.3-pter. Genomics 1991;10: 1100-2.
9. Williamson JA, Bosher JM, Skinner A, Sheer D, Williams T, Hurst HC. Chromosomal mapping of the human and mouse homologues of two new members of the AP-2 family of transcription factors. Genomics 1996;35:262-4.
10. Zhao F, Satoda M, Licht JD, Hayashizaki Y, Gelb BD. Cloning and characterization of a novel mouse AP-2 transcription factor, AP-2delta, with unique DNA binding and transactivation properties. J Biol Chem 2001;276:40755-60.
11. Feng W, Williams T. Cloning and characterization of the mouse AP-2 epsilon gene: a novel family member expressed in the developing olfactory bulb. Mol Cell Neurosci 2003;24:460-75.
12. Wang HV, Vaupel K, Buettner R, Bosserhoff AK, Moser M. Identification and embryonic expression of a new AP-2 transcription factor, AP-2 epsilon. Dev Dyn 2004;231:128-35.
13. Eckert D, Buhl S, Weber S, Jager R, Schorle H. The AP-2 family of transcription factors. Genome Biol 2005;6:246.
14. Bosher JM, Totty NF, Hsuan JJ, Williams T, Hurst HC. A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Oncogene 1996;13:1701-7.
15. Hilger-Eversheim K, Moser M, Schorle H, Buettner R. Regulatory roles of AP-2 transcription factors in vertebrate development, apoptosis and cell-cycle control. Gene 2000;260:1-12.
16. Zeng YX, Somasundaram K, el-Deiry WS. AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. Nat Genet 1997;15:78-82.
17. McPherson LA, Baichwal VR, Weigel RJ. Identification of ERF-1 as a member of the AP2 transcription factor family. Proc Natl Acad Sci USA 1997;94:4342-7.
18. Bosher JM, Williams T, Hurst HC. The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. Proc Natl Acad Sci USA 1995;92:744-7.
19. McPherson LA, Weigel RJ. AP2alpha and AP2gamma: a comparison of binding site specificity and trans-activation of the estrogen receptor promoter and single site promoter constructs. Nucleic Acids Res 1999;27:4040-9.
20. Wu F, Lee AS. YY1 as a regulator of replication-dependent hamster histone H3.2 promoter and an interactive partner of AP-2. J Biol Chem 2001;276:28-34.
21. Mertens PR, Alfonso-Jaume MA, Steinmann K, Lovett DH. A synergistic interaction of transcription factors AP2 and YB-1 regulates gelatinase A enhancer-dependent transcription. J Biol Chem 1998;273: 32957-65.
22. McPherson LA, Loktev AV, Weigel RJ. Tumor suppressor activity of AP2alpha mediated through a direct interaction with p53. J Biol Chem 2002;277:45028-33.
23. Pena P, Reutens AT, Albanese C, D'Amico M, Watanabe G, Donner A, Shu IW, Williams T, Pestell RG. Activator protein-2 mediates transcriptional activation of the CYP11A1 gene by interaction with Sp1 rather than binding to DNA. Mol Endocrinol 1999;13:1402-16.
24. Batsche E, Muchardt C, Behrens J, Hurst HC, Cremisi C. RB and c-Myc activate expression of the E-cadherin gene in epithelial cells through interaction with transcription factor AP-2. Mol Cell Biol 1998;18:3647-58.
25. Sivak JM, West-Mays JA, Yee A, Williams T, Fini ME. Transcription factors Pax6 and AP-2alpha interact to coordinate corneal epithelial repair by controlling expression of matrix metalloproteinase gelatinase B. Mol Cell Biol 2004;24:245-57.
26. Wu F, Lee AS. CDP and AP-2 mediated repression mechanism of the replication-dependent hamster histone H3.2 promoter. J Cell Biochem 2002;84:699-707.
27. Mori N, Prager D. High levels of AP-2-binding activity in cell lines infected with human T-cell leukemia virus type I: possible enhancement of AP-2 binding by human T-cell leukemia virus type I tax. Cancer Res 1996;56:779-82.
28. Somasundaram K, Jayaraman G, Williams T, Moran E, Frisch S, Thimmapaya B. Repression of a matrix metalloprotease gene by E1A correlates with its ability to bind to cell type-specific transcription factor AP-2. Proc Natl Acad Sci USA 1996;93:3088-93.
29. Aqeilan RI, Palamarchuk A, Weigel RJ, Herrero JJ, Pekarsky Y, Croce CM. Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2gamma transcription factor. Cancer Res 2004;64:8256-61.
30. Ding X, Fan C, Zhou J, Zhong Y, Liu R, Ren K, Hu X, Luo C, Xiao S, Wang Y, Feng D, Zhang J. GAS41 interacts with transcription factor AP-2beta and stimulates AP-2beta-mediated transactivation. Nucleic Acids Res 2006;34:2570-8.
31. Kannan P, Yu Y, Wankhade S, Tainsky MA. PolyADP-ribose polymerase is a coactivator for AP-2-mediated transcriptional activation. Nucleic Acids Res 1999;27:866-74.
32. Li Q, Dashwood RH. Activator protein 2alpha associates with adenomatous polyposis coli/beta-catenin and inhibits beta-catenin/T-cell factor transcriptional activity in colorectal cancer cells. J Biol Chem 2004;279:45669-75.
33. Braganca J, Eloranta JJ, Bamforth SD, Ibbitt JC, Hurst HC, Bhattacharya S. Physical and functional interactions among AP-2 transcription factors, p300/CREB-binding protein, and CITED2. J Biol Chem 2003;278:16021-9.
34. Braganca J, Swingler T, Marques FT, Jones T, Eloranta JJ, Hurst HC, Shioda T, Bhattacharya S. Human CREB-binding protein/p300-interacting transactivator with ED-rich tail (CITED) 4, a new member of the CITED family, functions as a co-activator for transcription factor AP-2. J Biol Chem 2002;277:8559-65.
35. Kannan P, Tainsky MA. Coactivator PC4 mediates AP-2 transcriptional activity and suppresses ras-induced transformation dependent on AP-2 transcriptional interference. Mol Cell Biol 1999;19: 899-908.
36. Campillos M, Garcia MA, Valdivieso F, Vazquez J. Transcriptional activation by AP-2alpha is modulated by the oncogene DEK. Nucleic Acids Res 2003;31:1571-5.
37. Yagi R, Chen LF, Shigesada K, Murakami Y, Ito Y. A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J 1999;18:2551-62.
38. Garcia MA, Campillos M, Marina A, Valdivieso F, Vazquez J. Transcription factor AP-2 activity is modulated by protein kinase A-mediated phosphorylation. FEBS Lett 1999;444:27-31.
39. Eloranta JJ, Hurst HC. Transcription factor AP-2 interacts with the SUMO-conjugating enzyme UBC9 and is sumolated in vivo. J Biol Chem 2002;277:30798-804.
40. Turner BC, Zhang J, Gumbs AA, Maher MG, Kaplan L, Carter D, Glazer PM, Hurst HC, Haffty BG, Williams T. Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways. Cancer Res 1998;58:5466-72.
41. Jager R, Werling U, Rimpf S, Jacob A, Schorle H. Transcription factor AP-2gamma stimulates proliferation and apoptosis and impairs differentiation in a transgenic model. Mol Cancer Res 2003;1:921-9.
42. Ruiz M, Pettaway C, Song R, Stoeltzing O, Ellis L, Bar-Eli M. Activator protein 2alpha inhibits tumorigenicity and represses vascular endothelial growth factor transcription in prostate cancer cells. Cancer Res 2004;64:631-8.
43. Zhang J, Brewer S, Huang J, Williams T. Overexpression of transcription factor AP-2alpha suppresses mammary gland growth and morphogenesis. Dev Biol 2003;256:127-415.
44. Nottoli T, Hagopian-Donaldson S, Zhang J, Perkins A, Williams T. AP-2-null cells disrupt morphogenesis of the eye, face, and limbs in chimeric mice. Proc Natl Acad Sci USA 1998;95:13714-19.
45. Schorle H, Meier P, Buchert M, Jaenisch R, Mitchell PJ. Transcription factor AP-2 essential for cranial closure and craniofacial development. Nature 1996;381:235-8.
46. Zhang J, Hagopian-Donaldson S, Serbedzija G, Elsemore J, Plehn-Dujowich D, McMahon AP, Flavell RA, Williams T. Neural tube, skeletal and body wall defects in mice lacking transcription factor AP-2. Nature 1996;381:238-41.
47. Moser M, Dahmen S, Kluge R, Grone H, Dahmen J, Kunz D, Schorle H, Buettner R. Terminal renal failure in mice lacking transcription factor AP-2 beta. Lab Invest 2003;83:571-8.
48. Moser M, Pscherer A, Roth C, Becker J, Mucher G, Zerres K, Dixkens C, Weis J, Guay-Woodford L, Buettner R, Fassler R. Enhanced apoptotic cell death of renal epithelial cells in mice lacking transcription factor AP-2beta. Genes Dev 1997;11:1938-48.
49. Satoda M, Zhao F, Diaz GA, Bum J, Goodship J, Davidson HR, Pierpont ME, Gelb BD. Mutations in TFAP2B cause Char syndrome, a familial form of patent ductus arteriosus. Nat Genet 2000;25:42-6.
50. Auman HJ, Nottoli T, Lakiza O, Winger Q, Donaldson S, Williams T. Transcription factor AP-2gamma is essential in the extra-embryonic lineages for early postimplantation development. Development 2002;129:2733-47.
51. Werling U, Schorle H. Transcription factor gene AP-2 gamma essential for early murine development. Mol Cell Biol 2002;22:3149-56.
52. Bar-Eli M. Gene regulation in melanoma progression by the AP-2 transcription factor. Pigment Cell Res 2001;14:78-85.
53. Huang S, Jean D, Luca M, Tainsky MA, Bar-Eli M. Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis. EMBO J 1998;17:4358-69.
54. Jean D, Gershenwald JE, Huang S, Luca M, Hudson MJ, Tainsky MA, Bar-Eli M. Loss of AP-2 results in up-regulation of MCAM/ MUC18 and an increase in tumor growth and metastasis of human melanoma cells. J Biol Chem 1998;273:16501-8.
55. Tellez C, McCarty M, Ruiz M, Bar-Eli M. Loss of activator protein-2alpha results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. J Biol Chem 2003;278:46632-42.
56. Gershenwald JE, Sumner W, Calderone T, Wang Z, Huang S, BarEli M. Dominant-negative transcription factor AP-2 augments SB-2 melanoma tumor growth in vivo. Oncogene 2001;20:3363-75.
57. Karjalainen JM, Kellokoski JK, Eskelinen MJ, Alhava EM, Kosma VM. Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma. J Clin Oncol 1998;16:3584-91.
58. Ruiz M, Troncoso P, Bruns C, Bar-Eli M. Activator protein 2alpha transcription factor expression is associated with luminal differentiation and is lost in prostate cancer. Clin Cancer Res 2001;7:4086-95.
59. Lipponen P, Aaltomaa S, Kellokoski J, Ala-Opas M, Kosma V. Expression of activator protein 2 in prostate cancer is related to tumor differentiation and cell proliferation. Eur Urol 2000;37:573-8.
60. Sumigama S, Ito T, Kajiyama H, Shibata K, Tamakoshi K, Kikkawa F, Williams T, Tainsky MA, Nomura S, Mizutani S. Suppression of invasion and peritoneal carcinomatosis of ovarian cancer cells by overexpression of AP-2alpha. Oncogene 2004;23:5496-504.
61. Anttila MA, Kellokoski JK, Moisio KI, Mitchell PJ, Saarikoski S, Syrjanen K, Kosma VM. Expression of transcription factor AP-2alpha predicts survival in epithelial ovarian cancer. Br J Cancer 2000; 82:1974-83.
62. Odegaard E, Staff AC, Kaern J, Florenes VA, Kopolovic J, Trope CG, Abeler VM, Reich R, Davidson B. The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma. Gynecol Oncol 2005;100:462-8.
63. Heimberger AB, McGary EC, Suki D, Ruiz M, Wang H, Fuller GN, Bar-Eli M. Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas. Clin Cancer Res 2005;11:267-72.
64. Ropponen KM, Kellokoski JK, Pirinen RT, Moisio KI, Eskelinen MJ, Alhava EM, Kosma VM. Expression of transcription factor AP-2 in colorectal adenomas and adenocarcinomas; comparison of immunohistochemistry and in situ hybridisation. J Clin Pathol 2001; 54:533-8.
65. Ropponen KM, Kellokoski JK, Lipponen PK, Pietilainen T, Eskelinen MJ, Alhava EM, Kosma VM. p21/WAF1 expression in human colorectal carcinoma: association with p53, transcription factor AP-2 and prognosis. Br J Cancer 1999;81:133-40.
66. Hoei-Hansen CE, Nielsen JE, Almstrup K, Sonne SB, Graem N, Skakkebaek NE, Leffers H, Rajpert-De Meyts E. Transcription factor AP-2gamma is a developmentally regulated marker of testicular carcinoma in situ and germ cell tumors. Clin Cancer Res 2004;10:8521-30.
67. Pauls K, Jager R, Weber S, Wardelmann E, Koch A, Buttner R, Schorle H. Transcription factor AP-2gamma, a novel marker of gonocytes and seminomatous germ cell tumors. Int J Cancer 2005;115:470-7.
68. Hoei-Hansen CE, Rajpert-De Meyts E, Carlsen E, Almstrup K, Leffers H, Skakkebaek NE. A subfertile patient diagnosed with testicular carcinoma in situ by immunocytological staining for AP-2gamma in semen samples: case report. Hum Reprod 2005;20:579-82.
69. Hietala KA, Kosma VM, Syrjanen KJ, Syrjanen SM, Kellokoski JK. Correlation of MIB-1 antigen expression with transcription factors Skn- 1, Oct-1, AP-2, and HPV type in cervical intraepithelial neoplasia. J Pathol 1997;183:305-10.
70. Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD, Lunec J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res 1997;57:3272-80.
71. Oya M, Mikami S, Mizuno R, Miyajima A, Horiguchi Y, Nakashima J, Marumo K, Mukai M, Murai M. Differential expression of activator protein-2 isoforms in renal cell carcinoma. Urology 2004;64:162-7.
72. Oyama N, Takahashi H, Tojo M, Iwatsuki K, Iizuka H, Nakamura K, Homma Y, Kaneko F. Different properties of three isoforms (alpha, beta, and gamma) of transcription factor AP-2 in the expression of human keratinocyte genes. Arch Dermatol Res 2002;294:273-80.
73. Friedrichs N, Jager R, Paggen E, Rudlowski C, Merkelbach-Bruse S, Schorle H, Buettner R. Distinct spatial expression patterns of AP-2alpha and AP-2gamma in non-neoplastic human breast and breast cancer. Mod Pathol 2005;18:431-8.
74. Gee JM, Robertson JF, Ellis IO, Nicholson RI, Hurst HC. Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer. J Pathol 1999;189:514-20.
75. Pellikainen J, Kataja V, Ropponen K, Kellokoski J, Pietilainen T, Bohm J, Eskelinen M, Kosma VM. Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer. Clin Cancer Res 2002;8:3487-95.
76. Li M, Wang Y, Yu Y, Nishizawa M, Nakajima T, Ito S, Kannan P. The human transcription factor activation protein-2 gamma (AP-2gamma): gene structure, promoter, and expression in mammary carcinoma cell lines. Gene 2002;301:43-51.
77. Korkola JE, DeVries S, Fridlyand J, Hwang ES, Estep AL, Chen YY, Chew KL, Dairkee SH, Jensen RM, Waldman FM. Differentiation of lobular versus ductal breast carcinomas by expression microarray analysis. Cancer Res 2003;63:7167-75.
78. Berger AJ, Davis DW, Tellez C, Prieto VG, Gershenwald JE, Johnson MM, Rimm DL, Bar-Eli M. Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res 2005;65:11185-92.
79. Mazina OM, Phillips MA, Williams T, Vines CA, Cherr GN, Rice RH. Redistribution of transcription factor AP-2alpha in differentiating cultured human epidermal cells. J Invest Dermatol 2001;117: 864-70.
80. Jager R, Friedrichs N, Heim I, Buttner R, Schorle H. Dual role of AP-2gamma in ErbB-2-induced mammary tumorigenesis. Breast Cancer Res Treat 2005;90:273-80.
81. Richardson BD, Cheng YH, Langland RA, Handwerger S. Differential expression of AP-2gamma and AP-2alpha during human trophoblast differentiation. Life Sci 2001;69:2157-65.
82. Pfisterer P, Ehlermann J, Hegen M, Schorle H. A subtractive gene expression screen suggests a role of transcription factor AP-2 alpha in control of proliferation and differentiation. J Biol Chem 2002;277: 6637-44.
83. Pellikainen J. Activator Protein -2 in Breast Cancer; Relation to Cell Growth, Differentiation and Cell-Matrix Interactions. PhD thesis. Kuopio University Publicatios, D. Medical Sciences 339. Kuopio, Kopijyvä. 2004. 106p
84. Wajapeyee N, Somasundaram K. Cell cycle arrest and apoptosis induction by activator protein 2alpha (AP-2alpha) and the role of p53 and p21WAF1/CIP1 in AP-2alpha-mediated growth inhibition. J Biol Chem 2003;278:52093-101.
85. Pellikainen MJ, Pekola TT, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM. p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis. J Clin Pathol 2003;56:214-20.
86. Stabach PR, Thiyagarajan MM, Woodfield GW, Weigel RJ. AP2alpha alters the transcriptional activity and stability of p53. Oncogene 2006;25:2148-59.
87. Wajapeyee N, Raut CG, Somasundaram K. Activator protein 2alpha status determines the chemosensitivity of cancer cells: implications in cancer chemotherapy. Cancer Res 2005;65:8628-34.
88. Nyormoi O, Wang Z, Doan D, Ruiz M, McConkey D, Bar-Eli M. Transcription factor ap-2alpha is preferentially cleaved by caspase 6 and degraded by proteasome during tumor necrosis factor alpha-induced apoptosis in breast cancer cells. Mol Cell Biol 2001;21:4856-67.
89. Gaubatz S, Imhof A, Dosch R, Werner O, Mitchell P, Buettner R, Eilers M. Transcriptional activation by Myc is under negative control by the transcription factor AP-2. EMBO J 1995;14:1508-19.
90. Decary S, Decesse JT, Ogryzko V, Reed JC, Naguibneva I, Harel-Bellan A, Cremisi CE. The retinoblastoma protein binds the promoter of the survival gene bcl-2 and regulates its transcription in epithelial cells through transcription factor AP-2. Mol Cell Biol 2002;22:7877-88.
91. Li H, Goswami PC, Domann FE. AP-2gamma induces p21 expression, arrests cell cycle, and inhibits the tumor growth of human carcinoma cells. Neoplasia 2006;8:568-77.
92. Tanner MM, Tixkkonen M, Kallioniemi A, Collins C, Stokke T, Karhu R, Kowbel D, Shadravan F, Hintz M, Kuo WL. Increased copy number at 20q13 in breast cancer: defining the critical region and exclusion of candidate genes. Cancer Res 1994;54:4257-60.
93. Zhao C, Yasui K, Lee CJ, Kurioka H, Hosokawa Y, Oka T, Inazawa J. Elevated expression levels of NCOA3, TOP1, and TFAP2C in breast tumors as predictors of poor prognosis. Cancer 2003;98:18-23.
94. Schuur ER, McPherson LA, Yang GP, Weigel RJ. Genomic structure of the promoters of the human estrogen receptor-alpha gene demonstrate changes in chromatin structure induced by AP2gamma. J Biol Chem 2001;276:15519-26.
95. deConinck EC, McPherson LA, Weigel RJ. Transcriptional regulation of estrogen receptor in breast carcinomas. Mol Cell Biol 1995;15:2191-6.
96. Orso F, Cottone E, Hasleton MD, Ibbitt JC, Sismondi P, Hurst HC, De Bortoli M. Activator protein-2gamma (AP-2gamma) expression is specifically induced by oestrogens through binding of the oestrogen receptor to a canonical element within the 5′-untranslated region. Biochem J 2004;377:429-38.
97. Perissi V, Menini N, Cottone E, Capello D, Sacco M, Montaldo F, De Bortoli M. AP-2 transcription factors in the regulation of ERBB2 gene transcription by oestrogen. Oncogene 2000;19:280-8.
98. Ross JS, Fletcher JA HER-2/neu (c-erb-B2) gene and protein in breast cancer. Am J Clin Pathol. 112:S53-S67, 1999.
99. Vogel C, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ. First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer 2001;37 Suppl 1:S25-S29.
100. Hurst HC. Update on HER-2 as a target for cancer therapy: The ERBB2 promoter and its exploitation for cancer treatment. Breast Cancer Res 2001;3:395-8.
101. Johnson AC. Activation of epidermal growth factor receptor gene transcription by phorbol 12-myristate 13-acetate is mediated by activator protein 2. J Biol Chem 1996;271:3033-8.
102. Skinner A, Hurst HC. Transcriptional regulation of the c-erbB-3 gene in human breast carcinoma cell lines. Oncogene 1993;8:3393-401.
103. Zhu CH, Domann FE. Dominant negative interference of transcription factor AP-2 causes inhibition of ErbB-3 expression and suppresses malignant cell growth. Breast Cancer Res Treat 2002;71:47-57.
104. Hollywood DP, Hurst HC. A novel transcription factor, OB2-1, is required for overexpression of the proto-oncogene c-erbB-2 in mammary tumour lines. EMBO J 1993;12:2369-75.
105. Yeretssian G, Lecocq M, Lebon G, Hurst HC, Sakanyan V. Competition on nitrocellulose-immobilized antibody arrays: from bacterial protein binding assay to protein profiling in breast cancer cells. Mol Cell Proteomics 2005;4:605-17.
106. Vernimmen D, Begon D, Salvador C, Gofflot S, Grooteclaes M, Winkler R. Identification of HTF (HER2 transcription factor) as an AP-2 (activator protein-2) transcription factor and contribution of the HTF binding site to ERBB2 gene overexpression. Biochem J 2003;370: 323-9.
107. Delacroix L, Begon D, Chatel G, Jackers P, Winkler R. Distal ERBB2 promoter fragment displays specific transcriptional and nuclear binding activities in ERBB2 overexpressing breast cancer cells. DNA Cell Biol 2005;24:582-94.
108. Newman SP, Bates NP, Vernimmen D, Parker MG, Hurst HC. Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. Oncogene 2000;19:490-7.
109. Pellikainen J, Naukkarinen A, Ropponen K, Rummukainen J, Kataja V, Kellokoski J, Eskelinen M, Kosma V.-M. Expression of HER2 and its association with AP-2 in breast cancer. Eur J Cancer 2004;40: 1485-95.
110. Li M, Wang Y, Hung MC, Kannan P. Inefficient proteasomal-degradation pathway stabilizes AP-2alpha and activates HER-2/neu gene in breast cancer. Int J Cancer 2005;118:802-11.
111. Yu Y, Wang Y, Li M, Kannan P. Tumorigenic effect of transcription factor hAP-2alpha and the intricate link between hAP-2alpha activation and squelching. Mol Carcinog 2002;34:172-9.
112. Clark IM, Rowan AD, Edwards DR, Bech-Hansen T, Mann DA, Bahr MJ, Cawston TE. Transcriptional activity of the human tissue inhibitor of metalloproteinases 1 (TIMP-1) gene in fibroblasts involves elements in the promoter, exon 1 and intron 1. Biochem J 1997;324:611-7.
113. Huhtala P, Chow LT, Tryggvason K. Structure of the human type IV collagenase gene. J Biol Chem 1990;265:11077-82.
114. Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004;10: 7621-8.
115. Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 1997;57:1199-205.
116. Schewe DM, Leupold JH, Boyd DD, Lengyel ER, Wang H, Gruetzner KU, Schildberg FW, Jauch KW, Allgayer H. Tumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series of resected gastrointestinal cancers. Clin Cancer Res 2003;9:2267-76.
117. Schewe DM, Biller T, Maurer G, Asangani IA, Leupold JH, Lengyel ER, Post S, Allgayer H. Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers. Clin Cancer Res 2005;11:8538-48.